Schizophrenia Research
Volume 112, Issue 1 , Pages 32-45, July 2009

Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona:

The rapporteurs' report

  • Stefan J. Borgwardt

      Affiliations

    • University Hospital Basel, Psychiatric Outpatient Department, Petersgraben 4, CH-4031 Basel, Switzerland
    • King's College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
  • ,
  • Chandlee Dickey

      Affiliations

    • The Brockton Boston VA Healthcare System, Psychiatry, 116A, 940 Belmont Avenue, Brockton, Massachusetts, 02301, United States
    • Harvard Medical School, Boston, Massachusetts USA
  • ,
  • Hilleke Hulshoff Pol

      Affiliations

    • The University of Utrecht, Utrecht, The Netherlands
  • ,
  • Thomas J. Whitford

      Affiliations

    • Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, United States
    • Tel.: +1 617 525 6119; fax: +1 617 525 6150.
  • ,
  • Lynn E. DeLisi

      Affiliations

    • The Brockton Boston VA Healthcare System, Psychiatry, 116A, 940 Belmont Avenue, Brockton, Massachusetts, 02301, United States
    • Harvard Medical School, Boston, Massachusetts USA
    • Corresponding Author InformationCorresponding author.

Received 23 February 2009; received in revised form 19 April 2009; accepted 21 April 2009. published online 25 May 2009.

Abstract 

In 1990 a satellite session of the American College of Neuropsychopharmacology (ACNP) Annual Meeting was held that focused on the question of whether progressive changes in brain structure occur in schizophrenia and this session raised considerable controversy. Eighteen years later, on December 12, 2008, after much data have since accumulated on this topic, a group of approximately 45 researchers gathered after the annual ACNP meeting to participate in a similar workshop on several unresolved questions still remaining: (1) How strong and consistent is the evidence? (2) Is there anatomic specificity to changes and is it disease specific or subject specific? (3) What is the time course? (4) What is the underlying pathophysiology (i.e. is it central to the disease process or is it due to neuroleptic treatment or other epiphenomena? (5) What is its clinical significance? and (6) Are there treatment implications?

The day was chaired by Lynn E. DeLisi and co-chaired by Stephen J. Wood. Christos Pantelis and Jeffrey A. Lieberman extensively helped with its planning. The ACNP assisted in its organization as an official satellite of its annual meeting and several pharmaceutical companies provided support with unrestricted educational grants. The following is a summary of the sessions as recounted by rapporteurs whose job was to record as closely as possible the outcome of discussions on the above outlined questions.

Keywords: Progression, ventricular enlargement, brain structure, temporal lobe, frontal lobe, prodrome, 1st episode ,schizophrenia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Rapporteurs are alphabetically listed. Each equally contributed to this report.

PII: S0920-9964(09)00212-6

doi:10.1016/j.schres.2009.04.025

Schizophrenia Research
Volume 112, Issue 1 , Pages 32-45, July 2009